MARGINAL ZONE LYMPHOMA

This study compares standard radiation (24 Gy) to a very low dose (4 Gy) for people with follicular or marginal zone lymphoma. The goal is to see if the low dose works just as well but causes fewer side effects. About 375 participants will be enrolled, and the study is currently …

This study tests a new vaccine (EO2463) for people with slow-growing non-Hodgkin's lymphoma. The vaccine is designed to help the immune system attack cancer cells. It is given alone or with standard drugs. About 80 adults with follicular or marginal zone lymphoma will take part. …

This study tests whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has returned or not responded to prior therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib. Researchers want to see how the drug affects quality of life and how often patients need hospital care. Th…

This study tests a new drug called BGB-16673 for people with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The goal is to find the best dose and see if it is safe and shrinks tumors. About 146 Chinese adults will take part in this …

This study is for people with certain blood cancers (like CLL or lymphoma) who are starting a type of targeted drug called a BTK inhibitor. These drugs can raise blood pressure and increase the risk of heart problems. The study will test whether carefully managing any new or wors…

This early-stage study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. T…

This study tests whether combining two drugs, rituximab and zanubrutinib, is safe and works well for people with untreated follicular lymphoma or marginal zone lymphoma. About 43 adults will take the drugs and be monitored for tumor response and side effects. The goal is to contr…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated, slow-growing types of non-Hodgkin lymphoma, including follicular lymphoma. The goal is to see if this drug pair can shrink or eliminate cancer. About 49 adults will take part. T…

This study tests a drug called loncastuximab tesirine in 50 adults with marginal zone lymphoma that has returned or not responded to prior therapy. The drug is designed to deliver a toxin directly to cancer cells. Researchers will measure how many participants achieve complete re…

This study tests whether combining rituximab (an antibody) with venetoclax (a targeted pill) can effectively treat marginal zone lymphoma that hasn't been treated before. About 33 adults with measurable disease will receive the drug combo, and researchers will measure how many ac…

This study looks at how well a combination of two drugs, zanubrutinib and rituximab, works as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo and be followed to see if their tumors shrink or dis…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This study tests whether the drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a type of blood cancer. About 25 adults will receive the treatment to see if it leads to complete remission. The goal is to control the disease, not cure it, as ongoing mana…

This study tests a new drug, orelabrutinib, combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a rare blood cancer. About 69 participants will receive the treatment to see if it improves tumor shrinkage and helps control the disease long-term. The …

This study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The main goal is to see if the drug can shrink tumors. About 27 people will take part, and the study is cu…

This study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…

This study tests a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo works at shrinking tumors and to check…

This study tests a two-drug combination (mosunetuzumab and lenalidomide) as the first treatment for adults with follicular or marginal zone lymphoma. Participants receive the drugs in cycles, with adjustments based on how well the cancer responds. The goal is to see how many peop…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with certain B cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The goal is to see if these specially engineere…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had treatment before. The goal is to see if the drug can shrink or eliminate the cancer. Participants take the drug as a pill, and doctors monitor…

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This early-phase study tests a new treatment for adults with B-cell lymphomas (like non-Hodgkin lymphoma) that have come back or not responded to prior therapies. It combines a targeted oral drug (pirtobrutinib) with specially engineered immune cells (LV20.19 CAR T-cells). The go…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests a new treatment called CTX112 for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor immune cells that can target and kill cancer cells. The trial…

This study tests whether two drugs, pirtobrutinib and rituximab, can shrink or control tumors in people with newly diagnosed marginal zone lymphoma. About 23 adults who have not had prior treatment (except for certain antibiotics or antivirals) will receive the combination. The m…

This study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…

This early-phase study tests an experimental oral drug called LP-168 in about 60 adults with several types of B-cell blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how t…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study will follow 2,500 adults newly diagnosed with marginal zone B-cell lymphoma to learn more about the disease, how it is treated, and what happens over time. Researchers will collect medical information and biological samples to understand different subtypes and treatmen…